問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of General Surgery

Division of Urology

更新時間：2023-09-19

郭永嘉Kao, Yung-Chia
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

79Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭永嘉

List

128Cases

2019-11-01 - 2023-01-31

Phase II/III

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cance

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Bintrafusp alfa (M7824)

Participate Sites
7Sites

Recruiting7Sites

2021-11-01 - 2027-03-20

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-03-25 - 2025-10-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-08-01 - 2026-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2016-05-01 - 2018-09-30

Phase III

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

  • Condition/Disease

    Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

  • Test Drug

    avelumab

Participate Sites
10Sites

Terminated9Sites

陳仁熙
Linkou Chang Gung Medical Foundation

白禮源
China Medical University Hospital-Taipei

未分科

2015-10-01 - 2017-02-15

Phase III

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma

  • Condition/Disease

    unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma

  • Test Drug

    Avelumab

Participate Sites
7Sites

Terminated5Sites

Study ended1Sites

2018-06-15 - 2021-06-30

Phase III

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer(EV-301)

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    enfortumab vedotin

Participate Sites
6Sites

Recruiting5Sites

Study ended1Sites

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-07-30 - 2020-09-30

Phase III

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Condition/Disease

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    IMAB362

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

洪逸平
Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-09-15 - 2019-02-28

Phase II

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Ramucirumab

Participate Sites
6Sites

Terminated5Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2015-09-07 - 2020-06-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma

  • Condition/Disease

    Advanced or Metastatic Soft Tissue Sarcoma

  • Test Drug

    Olaratumab (LY3012207)

Participate Sites
3Sites

Terminated3Sites

顏厥全
Taipei Veterans General Hospital

Division of General Internal Medicine

1 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB